About the Article
Published as part of the Forbes India Risk Management Series, this article brings together senior leaders from India's pharmaceutical and healthcare sectors to discuss the key risks affecting the industry, with a particular focus on regulatory compliance, quality standards, and business continuity. The discussion examines how increasing regulatory scrutiny, evolving compliance requirements, and the need for robust governance continue to shape the healthcare landscape. Representing Zuvius Lifesciences, Nimish Thakkar highlights the company's uncompromising approach to quality, emphasizing that investments in quality systems take priority over marketing expenditure because even a single quality issue can have long-term consequences for a pharmaceutical company. The discussion also explores the industry's responsibility to maintain patient trust while adapting to changing regulatory expectations and technological advancements.
Key Highlights
- Features Nimish Thakkar among senior healthcare leaders.
- Explores why regulatory compliance remains a major challenge.
- Highlights Zuvius Lifesciences' commitment to quality.
- Discusses increasing regulatory scrutiny in pharma.
- Examines governance and technology in healthcare risk management.